Neidio i'r cynnwys
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Iaith
Pob Maes
Teitl
Awdur
Pwnc
Rhif Galw
ISBN/ISSN
Tag
Canfod
Uwch
Cetuximab plus Irinotecan as t...
Dyfynnu hwn
Anfonwch hwn fel neges destun
E-bostio hwn
Argraffu
Allforio Cofnod
Allforio i RefWorks
Allforio i EndNoteWeb
Allforio i EndNote
Permanent link
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
Manylion Llyfryddiaeth
Prif Awduron:
Moe, M
,
Micallef, R
,
Pwint, T
,
Maughan, T
,
Mort, D
,
Wagstaff, J
Fformat:
Journal article
Cyhoeddwyd:
2008
Daliadau
Disgrifiad
Eitemau Tebyg
Dangos Staff
Eitemau Tebyg
Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis
gan: Meysam Seyedifar, et al.
Cyhoeddwyd: (2024-10-01)
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
gan: Frifeldt Sanne K, et al.
Cyhoeddwyd: (2011-03-01)
Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
gan: Maria Ignez Freitas Melro Braghiroli, et al.
Cyhoeddwyd: (2024-01-01)
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
gan: Adams, R, et al.
Cyhoeddwyd: (2008)
First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
gan: Yu‐Wen Zhou, et al.
Cyhoeddwyd: (2021-05-01)